BRICS-funded development bank provides $320mln funding for Brazil's health sector: Report
Health Minister Alexandre Padilha said that Brazil is teaming with India to produce tuberculosis drugs and with China to produce insulin and the chickenpox vaccine, which will help overcome a global supply crisis.
The country has also signed partnerships to produce medical equipment such as CT scanners and radiotherapy devices, ensuring local availability of equipment.
Padilha stated that BRICS is focusing on investing in the health sector and the production of medicines and vaccines.
(Writing by P Deol; Editing by Anoop Menon)
(anoop.menon@lseg.com)
Subscribe to our Projects' PULSE newsletter that brings you trustworthy news, updates and insights on project activities, developments, and partnerships across sectors in the Middle East and Africa.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
a day ago
- Zawya
Parliament Approves land sublease for Kabale University expansion
Parliament has approved a motion allowing Kabale Regional Referral Hospital sublease five acres of land to Kabale University, clearing the way for the university to expand its Faculty of Medicine. The Minister of Health, Ruth Aceng presented the proposal during the plenary sitting of Thursday, 31 July 2025. Kabale University made the request in August 2022. The university aims to build new teaching and medical facilities, including specialized clinics, patient wards, lecture halls and operating rooms. Aceng said the move is a major boost for medical training and healthcare in southwestern Uganda noting that Kabale Regional Referral Hospital serves over 2.4 million people, including patients from Rwanda. 'This is more than just a land deal, it is an investment in better healthcare, stronger medical education and growth for the Kigezi sub-region and beyond,' Aceng said. She noted that the expansion will help the university train more doctors and nurses for the region, addressing a critical shortage of healthcare workers in districts like Kabale, Kanungu, Ntungamo, Kisoro and Rukungiri. Currently Kabale University's medical school operates out of run-down hospital building that is set for demolition. Aceng emphasised that the sublease will allow the university to create a modern medical school and teaching hospital. 'This will improve training, enhance research, and bring better healthcare closer to the communities that need it most,' she said. The Koboko Municipality MP, Hon. Charles Ayume said the motion was timely considering the state of the Medical school and its symbiotic relationship with the Regional Referral Hospital. 'A Medical school and hospital have a symbiotic relationship where they all benefit. The University does the teaching but the hospital benefits from extra services of lecturers and students during their training,' said Ayume adding that, 'We had queried the type of doctors that will come from that dilapidated building'. Tororo District Woman MP, Hon. Sarah Opendi asked fellow legislators to look into the status of Regional Referral Hospitals across the country, saying most are performing way below the capacity of a regional referral hospital. 'Kabale Regional Referral Hospital is challenged in terms of space and infrastructure, it remains a 100 bed capacity hospital which is below the requirement of a regional referral hospital,' Opendi said. She noted that most of the regional referral hospitals are understaffed between 25 to 30 percent staffing level, praying that it should be addressed in the next budget cycle. Distributed by APO Group on behalf of Parliament of the Republic of Uganda.
Zawya
a day ago
- Zawya
Nigeria: African Development Bank Approves $46 Million to Transform Healthcare in Sokoto State
The Board of Directors of the African Development Bank Group ( has approved a $46 million loan to finance the Sokoto State Health Infrastructure Project, a transformative initiative designed to enhance healthcare access and quality in Nigeria's Sokoto State. The project addresses critical health system gaps in Sokoto, where key indicators reflect a critical need for intervention. Only one in 20 children is fully vaccinated, while infant mortality stands at 104 deaths per 1,000 live births, nearly double Nigeria's national average of 63. Less than 14 percent of health facilities in the state have functional infrastructure, and there is just one doctor for every 8,285 people -- far below the World Health Organization's recommended ratio of 1:1,000. The Bank's financing will support the delivery of climate-smart health infrastructure across three levels of care. These include the construction and equipping of a 1,000-bed teaching hospital complex; three zonal hospitals with a combined capacity of 450 beds; and six primary healthcare canters strategically located to serve rural communities. The project also includes the rehabilitation of health training institutions and the development of a modern medical warehouse to strengthen pharmaceutical supply chains. "This investment illustrates our commitment to continue working with the Government to fill critical infrastructure gaps in Nigeria's health system while building resilient, climate-adapted healthcare facilities," said Abdul Kamara, Director General of the African Development Bank's Nigeria Office. "By strengthening healthcare infrastructure in Sokoto State, we are building hope and creating pathways to better health outcomes for millions of Nigerians." Aligned with Nigeria's National Development Plan (2021-2025) and the Health Sector Renewal Investment Initiative, the project is expected to generate approximately 2,500 jobs, with 60 percent of opportunities targeting youth and 30 percent women. In addition, the project will integrate electronic health infrastructure and renewable energy systems, ensuring sustainable, energy-efficient operations while reducing greenhouse gas emissions. Expanded capacity in local the medical and nursing schools will create 700 new training slots annually, helping to address the region's acute shortage of skilled health professionals. The initiative builds on the Bank's successful track record in Nigeria's health sector, where it has financed four health infrastructure projects totaling $117.68 million. It will leverage strategic partnerships with the United Nations Children's Fund, the World Health Organization, USAID, and other development actors to maximize impact and ensure comprehensive health system strengthening. The African Development Bank Group remains committed to enhancing the quality of life for Africa's people through targeted investments in resilient health infrastructure that drive inclusive growth and sustainable development across the continent. Distributed by APO Group on behalf of African Development Bank Group (AfDB).
Zawya
a day ago
- Zawya
Life Sciences on the Chinese Mainland – Vital signs: Diagnosing trends in the life sciences real estate market on the Chinese mainland
HONG KONG SAR - Media OutReach Newswire - 1 August 2025 - Cushman & Wakefield, a leading global real estate services firm, today released its Life Sciences on the Chinese Mainland – Vital signs: Diagnosing trends in the life sciences real estate market on the Chinese mainland report. It is based on in-depth interview surveys we conducted on professionals active in the life sciences sector on the Chinese mainland. The life sciences industry on the Chinese mainland is undergoing a transformative phase, driven by progressive policies, groundbreaking innovations, the emergence of influential life sciences companies, and strategic regional development. This report delves into the latest trends shaping the sector. Policy Landscape – National and Local Catalysts Reforms enacted in 2024-2025 have significantly accelerated sector development. Nationally, China relaxed restrictions on foreign investment in gene and cell therapy and allowed the establishment of wholly foreign-owned hospitals in key cities. Regulatory incentives – such as data protection and marketing exclusivity – have improved market access for innovative drugs. Locally, cities like Beijing, Shanghai, Shenzhen, Guangzhou, and Suzhou are rolling out targeted subsidies, fast-track approvals, and ecosystem-building programmes that directly benefit biotech development. Recent national policy initiatives on the Chinese mainland Types of policies Detail information Opening to Foreign Investment In 2024, China eased restrictions on foreign investments in stem cell research, gene therapy, and genetic diagnostics within Free Trade Zones (FTZs) like Beijing, Shanghai, Guangdong, and Hainan. Regulatory Incentives The State Council's Circular No. 53 introduced measures such as regulatory data protection and marketing exclusivity for select pharmaceutical products, including orphan and paediatric drugs. Wholly Foreign-Owned Hospitals China now permits the establishment of wholly foreign-owned hospitals in cities like Beijing, Shanghai, and Shenzhen, enhancing healthcare services and encouraging foreign investment. Source: Cushman & Wakefield Research Industry Innovation and Company Growth Chinese life sciences companies are moving beyond generic drug manufacturing toward innovative therapies. Firms like Akeso, BeiGene, Gracell, and Legend Biotech are now global players, leading in CAR-T, bispecific antibodies, and AI-assisted R&D. These companies are not only commercialising cutting-edge treatments but also attracting international investment and licensing agreements, reinforcing the Chinese mainland's global relevance in life sciences. Real Estate Development and Regional Hubs Innovation hubs such as Suzhou BioBAY, Zhangjiang Hi-Tech Park (Shanghai), and the Bioisland Innovation Centre (Guangdong) are central to regional clustering. These hubs offer end-to-end support, including shared labs, venture capital access, GMP-compliant facilities, and proximity to academic and clinical networks. The rise of second-tier innovation cities like Chengdu and Ningbo further expands growth corridors. The " R&D + Manufacturing + Service" ecosystem Source: Cushman & Wakefield Research Landlord Perspectives – Evolving Real Estate Models Real estate developers and landlords are adapting to sector-specific requirements through asset-light models, flexible leasing, and high-specification lab and production space. Tier-1 cities face saturation, but central and western regions exhibit healthy demand. Developers are incorporating advanced sustainability and compliance features to meet growing regulatory and ESG expectations, particularly in GMP and cleanroom environments. Digitalisation, environmental policies, and differentiated tenant strategies are shaping performance. Operators now focus on integrated ecosystems with platforms that link tenants to R&D services, policy benefits, and technology partners. Occupier Perspectives – Growth, Innovation, and Challenges Life sciences occupiers are navigating regulatory reform, rising compliance demands, and intensified market competition. Many are localising production and R&D, leveraging regional subsidies, and investing in AI-powered innovation platforms. Occupiers seek flexibility, proximity to talent and infrastructure, and co-located R&D and manufacturing to support accelerated innovation and operational agility. In real estate, demand is strongest for GMP-certified labs, modular production facilities, and shared innovation platforms. Occupiers emphasise location advantages, sustainability certifications (e.g., LEED, WELL), and integration into clusters that enable faster time-to-market. Tony Su, Managing Director, National Head of Industrial & Logistics Property Services, China, said, "Life sciences business parks on the Chinese mainland demonstrated clear regional differentiation, highlighting opportunities for strategic positioning. While Tier-1 cities saw more moderate performance due to broader macroeconomic factors and abundant supply, core cities in central and western regions recorded healthy occupancy rates, underpinned by strong industrial clustering and increasingly sophisticated ecosystems – contributing to steady growth in asset value." Johnathan Wei, President, Project & Occupier Services, China, said, "Several interviewed life sciences companies on the Chinese mainland achieved revenue growth supported by innovative products and favourable policy tailwinds. While overall growth remained modest for many, a select group reported strong performance, highlighting opportunities for differentiation". Andrew Chan, Managing Director, Head of Valuation & Advisory Services, Greater China, said," Looking ahead to 2025 and beyond, growth opportunities lie in AI-driven drug discovery, personalised medicine, advanced therapeutics (CGT, RNA), and green-certified facilities. Government policies continue to support innovation through fast-track approvals, rare disease funding, and subsidies aligned with dual-carbon and ESG goals". Shaun Brodie, Head of Research Content, Greater China, "Life sciences real estate is shifting from generic parks to specialised, digitally enabled campuses with high compliance and flexibility. Investment strategies increasingly emphasise long-term partnerships, collaborative operating models, and digital infrastructure. Both landlords and occupiers express cautious optimism, with strategic differentiation and regional targeting seen as keys to unlocking future value". Please click here to download the full report. Hashtag: #Cushman&Wakefield The issuer is solely responsible for the content of this announcement. About Cushman & Wakefield Cushman & Wakefield (NYSE: CWK) is a leading global commercial real estate services firm for property owners and occupiers with approximately 52,000 employees in nearly 400 offices and 60 countries. In Greater China, a network of 23 offices serves local markets across the region. In 2024, the firm reported revenue of $9.4 billion across its core services of Valuation, Consulting, Project & Development Services, Capital Markets, Project & Occupier Services, Industrial & Logistics, Retail, and others. Built around the belief that Better never settles, the firm receives numerous industry and business accolades for its award-winning culture. For additional information, visit or follow us on LinkedIn ( Cushman & Wakefield
